Canada markets closed

Novartis AG (NVS)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
102.84+0.27 (+0.26%)
At close: 04:00PM EDT
102.84 0.00 (0.00%)
After hours: 05:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close102.57
Open102.70
Bid102.83 x 800
Ask103.29 x 800
Day's Range102.28 - 103.00
52 Week Range92.19 - 108.78
Volume969,082
Avg. Volume1,595,961
Market Cap210.795B
Beta (5Y Monthly)0.47
PE Ratio (TTM)23.37
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.78 (3.68%)
Ex-Dividend DateMar 07, 2024
1y Target EstN/A
  • GlobeNewswire

    Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash

    Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the initial acceptance period is expected to occur on 23 May 2024Additional statutory acceptance period is expected to end on 30 May 2024 at 24:00 hours CESTTransaction strengthens the Novartis pipeline in oncology, adding pelabresib, a late-stage BET inhibitor for myelofibrosis and tulmimetostat, an early-s

  • GlobeNewswire

    Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA

    Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the EHA Plenary SessionLatest data from the Kisqali®* NATALEE trial, including efficacy endpoints for patients with node-negative stage II and III HR+/HER2- early breast cancerNew radioligand therapy portfolio data supporting overall platform leadership and ongoing expansion in research infrastructure an

  • GlobeNewswire

    Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

    – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for